Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial
Claire Gallois, Jean‐François Emile, Stéfano Kim, Carole Montérymard, Marine Gilabert, Jérémie Bez, Astrid Lièvre, Laëtitia Dahan, Pierre Laurent‐Puig, Laurent Mineur, Romain Coriat, Jean-Louis Legoux, Vincent Hautefeuille, Jean–Marc Phelip, Thierry Lecomte, Harry Sokol, Claude Capron, Violaine Randrian, Côme Lepage, Nicolas Loménie, Camille Kurtz, Julien Taı̈eb, David Tougeron
Topics & Concepts
PembrolizumabBevacizumabMedicineOxaliplatinColorectal cancerClinical endpointOncologyMicrosatellite instabilityInternal medicineChemotherapyCancerImmunotherapyRandomized controlled trialBiologyMicrosatelliteAlleleGeneBiochemistryCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer